FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de peptides

Snap-8

Acetyl Octapeptide-3 / SNAP-8 Peptide

Beauty & Skincare

SNAP-8 (Acetyl Octapeptide-3, also marketed as Acetyl Glutamyl Heptapeptide-1) is a topical cosmetic peptide consisting of eight amino acids that modulates the SNARE complex responsible for neurotransmitter release at the neuromuscular junction. Developed by Lipotec as an extension of the hexapeptide Argireline concept, SNAP-8 is marketed as a topical alternative to botulinum toxin for reducing expression lines and wrinkles. It competitively inhibits SNARE complex formation, theoretically reducing muscle contraction intensity and thereby diminishing dynamic wrinkles.

Mécanisme d'action

Octapeptide that mimics the N-terminal of SNAP-25, a key protein in the SNARE complex responsible for neurotransmitter release at neuromuscular junctions. Competitively inhibits SNARE complex formation, reducing muscle contraction intensity and thereby reducing expression lines.

Protocoles de recherche

Pour des fins de recherche uniquement. Pas de conseil médical.

Topical application only. Used at 3-10% concentration in serums applied twice daily to expression-line areas (forehead, crow's feet, glabella). Not injected. Continuous use required for maintained effect.

Notes de recherche

Clinical Research Status

SNAP-8 has been evaluated in manufacturer-sponsored clinical studies showing wrinkle depth reduction of up to 63% after 28 days of regular application at concentrations of 3-10% in cream formulations. Independent peer-reviewed clinical data is limited compared to manufacturer claims, with most published evidence coming from in vitro SNARE complex inhibition assays rather than controlled clinical trials. It is widely available in cosmetic formulations globally and does not require regulatory approval for topical cosmetic use.

Key Published Findings

In vitro studies demonstrate that SNAP-8 inhibits SNARE complex assembly by competing with SNAP-25 (Synaptosomal-Associated Protein of 25 kDa) for incorporation into the exocytosis machinery. Catecholamine release assays in chromaffin cells show dose-dependent reduction in vesicular fusion and neurotransmitter release at relevant peptide concentrations. The eight-amino acid sequence provides enhanced stability and potentially greater SNARE complex affinity compared to the shorter six-amino acid Argireline sequence.

Safety Profile

SNAP-8 has an excellent safety profile for topical application, with no systemic absorption concerns at cosmetic concentrations and no reported sensitization or irritation in patch testing studies. Unlike injectable botulinum toxin, topical SNAP-8 cannot produce muscle paralysis, ptosis, or other serious adverse effects associated with neuromuscular blockade. It is considered suitable for sensitive skin and periorbital use, with no reported phototoxicity or photoallergic reactions.

Comparison to Related Compounds

SNAP-8 is an elongated version of Argireline (Acetyl Hexapeptide-3), with two additional amino acids theoretically providing greater potency and stability in SNARE complex inhibition. Both peptides target the same mechanism but cannot replicate the complete muscle paralysis achieved by botulinum toxin injection, offering instead a modest reduction in muscle contraction intensity. Compared to Matrixyl which stimulates collagen production, SNAP-8 addresses a completely different aspect of aging (dynamic wrinkles vs. structural collagen loss) and the two are complementary in formulations.

Community Observations

Skincare communities generally report subtle but noticeable improvements in forehead lines and crow's feet with consistent use over 4-8 weeks. Users frequently note that SNAP-8 works best as part of a comprehensive anti-aging routine rather than as a standalone treatment, managing expectations relative to injectable alternatives. DIY skincare formulators commonly work with SNAP-8 solutions at 3-10% concentration, noting that higher concentrations do not necessarily produce proportionally better results.

Moitié de vie

N/A (topical)

Réconstitution

N/A (topical formulation)

Conservation

Lyophilisé

Room temperature. Protect from light.

Réconstitué

Store at room temperature. Stable in formulation for 12+ months.

Statut légal aux États-Unis

Cosmetic ingredient (unregulated)

Autres noms connus

Acetyl Octapeptide-3SNAP-8 Peptide

Questions fréquentes

Qu'est-ce que Snap-8 ?

SNAP-8 (Acetyl Octapeptide-3, also marketed as Acetyl Glutamyl Heptapeptide-1) is a topical cosmetic peptide consisting of eight amino acids that modulates the SNARE complex responsible for neurotransmitter release at the neuromuscular junction. Developed by Lipotec as an extension of the hexapeptide Argireline concept, SNAP-8 is marketed as a topical alternative to botulinum toxin for reducing expression lines and wrinkles. It competitively inhibits SNARE complex formation, theoretically reducing muscle contraction intensity and thereby diminishing dynamic wrinkles.

Comment agit Snap-8 ?

Octapeptide that mimics the N-terminal of SNAP-25, a key protein in the SNARE complex responsible for neurotransmitter release at neuromuscular junctions. Competitively inhibits SNARE complex formation, reducing muscle contraction intensity and thereby reducing expression lines.

Quel est le statut réglementaire de Snap-8 aux États-Unis ?

Cosmetic ingredient (unregulated)

Quelle est la demi-vie de Snap-8 ?

N/A (topical)

Sous quels autres noms Snap-8 est-il connu ?

Acetyl Octapeptide-3, SNAP-8 Peptide

Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.

Lire la déclaration complète